Sulpiride and risperidone treatment significantly improved the abnormal involuntary movements of two patients with Huntington's disease on both actometer and clinical assessments. However, treatment with risperidone, but not sulpiride, significantly improved the functional activities as assessed by the Functional Disability Scale. To the best of our knowledge this is the first report of the successful treatment of Huntington's disease with risperidone.
Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. (1986) Neuroleptic-induced extrapyramidal side-effects: clinical perspectives with ritanserin (R 55 667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res40: 492-499
2.
Dursun S.M., Andrews H., Reveley M.A. (1994) Computerised continuous assessment of abnormal involuntary movements in Huntington's disease; improvement by sulpiride. Br J Clin Pharmacol37:503P-504P
3.
Gower A.J. (1992) 5-HT receptors and cognitive function. In Marsden C A, Heal D J (eds), Central serotonin receptors and psychotropic drugs. Blackwell Scientific Publishers, pp. 239-259
4.
Harper P.S. (1991) Huntington's disease. Major problems in neurology 22. Saunders, London
5.
He H., Richardson J.S. (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol10:19-30
6.
National Institute of Mental Health, Abnormal Involuntary Movement Scale (AIMs) (1976) In Guy O O (ed), ECDEU assessment manual for psychopharmacology . Rockville, MD, US Department of Health, Education, and Welfare, p. 534
7.
Quinn N., Marsden C.D. (1984) A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatr47:844-847
8.
Reveley M.A., Dursun S.M., Andrews H. (1993) Abnormal saccadic eye movements in Huntington's disease and the effects of a trial use of sulpiride. J Psychopharmacol SupplA75
9.
Reveley M.A., Dursun S.M., Andrews H. (1994) Improvement of abnormal saccadic eye movements in Huntington's disease by sulpiride: a case study. J Psychopharmacol8: 262-265
10.
Reyntjens A., Gelders Y.G., Hoppenbrouwers M L J A, Vanden Bussche G. (1986) Thymosthenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res8: 205-211
11.
Shoulson I. (1981) Huntington's disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology31:1333-1335
12.
Tryon W.W. (1991) Activity measurement in psychology and medicine . Plenum Press, New York
13.
Vinar O., Molcan J., Nahunek K., Svestka J., Zapletalek M. (1989) Ritanserin in schizophrenic patients. Act Nerv Super31: 107-109
